InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

InnoCare 2025 Annual Results Earnings Call

InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

InnoCare Announces Key Developments of Critical Clinical Studies

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

InnoCare Announces Estimated Annual Results for 2025

Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology

Happy New Year | Embarking on the Next Golden Decade of Development

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China